HK$8.11
7.31%
Hong Kong, Oct 05, 04:08 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG5340S1093
Symbol
2105

Laekna Inc Stock price

HK$8.11
+1.31 19.26% 1M
-8.57 51.38% 6M
-5.46 40.24% YTD
-8.80 52.04% 1Y
-6.35 43.91% 3Y
-6.89 45.93% 5Y
-6.89 45.93% 10Y
-6.89 45.93% 20Y
Hong Kong, Closing price Mon, Oct 05 2026
-0.64 7.31%
ISIN
KYG5340S1093
Symbol
2105
Industry

Is Laekna Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$3.5b
Enterprise Value
HK$2.4b
Net debt
positive
Cash
HK$1.3b
Shares outstanding
446.5m
Valuation
P/E
negative
P/S | estimate
11.7 | 9.4
EV/Sales | estimate
7.9 | 6.4
EV/FCF | ex SBC
negative | -
P/B
2.5
Financial Health
Equity Ratio
83.4%
Return on Equity
-19.4%
ROCE
-8.2%
ROIC
-
Debt/Equity
0.1
Financials
Revenue | estimate
HK$300.8m | HK$375.1m
EBITDA
-
EBIT
HK$-114.8m
Net Income
HK$-119.7m
Free Cash Flow | ex SBC
HK$-139.8m | -
Growth
Revenue | estimate
- | 200.3%
EBITDA
-
EBIT
64.4%
Net Income
57.4%
Free Cash Flow
43.4%
Margin
Gross
84.0%
EBITDA
-
EBIT
-38.2%
Net
-39.8%
Free Cash Flow | ex SBC
-46.5% | -
More
EPS
HK$-0.3
FCF per Share
HK$-0.3
Short interest
-
Employees
83
Rev per Employee
HK$1.5m

Laekna Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Laekna Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Laekna Inc forecast:

Buy
90%
Hold
10%

Financial data from Laekna Inc

Jun '26
+/-
%
301 301
-
100%
- Direct Costs 48 48
-
16%
253 253
-
84%
- Selling and Administrative Expenses 144 144
43% 43%
48%
- Research and Development Expense 283 283
24% 24%
94%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -115 -115
64% 64%
-38%
Net Profit -120 -120
57% 57%
-40%

In millions HKD.

Don't miss a Thing! We will send you all news about Laekna Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Laekna, Inc. engages in the provision of clinical stage research and development of biopharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 83 full-time employees. The company went IPO on 2023-06-29. The firm is still in the research and development stage. The firm's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The firm mainly conducts business in the Chinese, America, European, Korean, and other markets.

Head office Cayman Islands
CEO Dr. Lu
Employees 83
Website www.laekna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today